在性结肠炎患者的生物治疗期间血清胆红素和总胆汁酸的变化:一项回顾性研究
Zhengyu Ren1, Zhewei Zhang2, Haichen Li1
1Department of Gastroenterology, First Affiliated Hospital, Xi'an Jiaotong University, Shaanxi, People's Republic of China.
Journal of inflammation research
|July 17, 2025
概括
血清间接胆红素 (sIBIL) 显示为一种非侵入性生物标志物,可用于监测接受生物治疗的性结肠炎 (UC) 患者,与疾病严重程度和缓解状态相关.
科学领域:
- 胃肠病学 胃肠病学
- 临床化学 临床化学
- 生物标志物发现发现
背景情况:
- 性结肠炎 (UC) 监测通常依赖于侵入性内镜手术.
- 需要使用非侵入性血清生物标志物来跟踪UC进展和治疗反应.
- 之前的研究表明,UC患者的血清间接胆红素 (sIBIL),血清总胆红素 (sTBIL) 和血清总胆酸 (sTBA) 的水平发生变化.
研究的目的:
- 评估sIBIL,sTBIL和sTBAs作为血清生物标志物的潜力,用于在生物治疗期间监测UC患者.
- 评估这些生物标志物的诊断价值,以区分UC患者与健康对照.
- 调查这些生物标志物与UC疾病严重程度和内镜发现之间的相关性.
主要方法:
- 对138名UC患者和150名对照进行了回顾性研究.
- 接收器操作特征 (ROC) 曲线分析用于诊断价值评估.
- 斯皮尔曼相关性用于评估生物标志物与疾病严重程度的相关性.
- 在72名UC患者的生物治疗期间生物标志物变化的分析,通过内镜缓解分层.
主要成果:
- 与对照组相比,UC患者的sIBIL,sTBIL和sTBA显著降低 (P <0.05).
- 这三种生物标志物都显示UC检测的诊断值中等 (P < 0.05).
- sIBIL水平与UC严重程度有负相关性,并且在生物治疗期间增加,特别是在实现内镜缓解的患者 (P <0.05) 中.
- 在26周后,缓解组的sIBIL水平明显高于非缓解组 (P <0.05).
- 在治疗期间,sTBAs显示出可变的趋势,缓解和非缓解组之间没有显著差异.
结论:
- sIBIL是一种潜在的非侵入性血清生物标志物,用于UC诊断和监测生物治疗反应.
- 在sTBAs的动态变化可能提供洞察力监测UC生物治疗.
- 需要进一步的研究才能充分阐明sTBA在UC管理中的作用.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
198
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
198
Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239
Chronic Bowel Disorders: Introduction
541
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
541
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
426
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
426
Inflammatory Bowel Disease I: Ulcerative Colitis
332
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
332
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
237
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
237


